{"id":8299,"date":"2022-07-13T23:47:15","date_gmt":"2022-07-13T23:47:15","guid":{"rendered":"https:\/\/marylanddailygazette.com\/t-cell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed\/"},"modified":"2022-07-13T23:47:15","modified_gmt":"2022-07-13T23:47:15","slug":"t-cell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/t-cell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed\/","title":{"rendered":"T-Cell Lymphoma Therapeutics Analysis | FDA and EU Approvals, Recents Breakthroughs, Clinical Trials, Emerging Therapies, and Key Companies | Autolus, Solasia, Soligenix, CRISPR Therapeutics, Affimed"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/t-cell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed\">T-Cell Lymphoma Therapeutics Analysis | FDA and EU Approvals, Recents Breakthroughs, Clinical Trials, Emerging Therapies, and Key Companies | Autolus, Solasia, Soligenix, CRISPR Therapeutics, Affimed<\/a><\/p>\n<div readability=\"6\"><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/07\/A9gNOL.jpeg\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"T-Cell Lymphoma Therapeutics Analysis | FDA and EU Approvals, Recents Breakthroughs, Clinical Trials, Emerging Therapies, and Key Companies | Autolus, Solasia, Soligenix, CRISPR Therapeutics, Affimed \" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/07\/A9gNOL.jpeg\" alt=\"T-Cell Lymphoma Therapeutics Analysis | FDA and EU Approvals, Recents Breakthroughs, Clinical Trials, Emerging Therapies, and Key Companies | Autolus, Solasia, Soligenix, CRISPR Therapeutics, Affimed \" width=\"225\"><\/a><\/p>\n<div class=\"quotes\" readability=\"7\">\n<p>\u201cDelveinsight Business Research LLP\u201d<\/p>\n<\/div>\n<\/div>\n<p>As per DelveInsight, the T-Cell Lymphoma Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&amp;D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.<\/p>\n<p dir=\"ltr\"><em>\u201c<strong>T-Cell Lymphoma Pipeline Insight, 2022<\/strong>\u201d report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the T-Cell Lymphoma Market.&nbsp;<\/em><\/p>\n<p dir=\"ltr\">The<strong> T-Cell Lymphoma Pipeline report <\/strong>embraces&nbsp;in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p dir=\"ltr\"><img decoding=\"async\" title=\"T-Cell Lymphoma Pipeline Analysis\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/07\/iF48xM.jpg\" alt=\"T-Cell Lymphoma Pipeline Analysis\"><\/p>\n<p><noscript><img decoding=\"async\" title=\"T-Cell Lymphoma Pipeline Analysis\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/07\/iF48xM.jpg\" alt=\"T-Cell Lymphoma Pipeline Analysis\"><\/noscript><\/p>\n<p dir=\"ltr\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>T-Cell Lymphoma Pipeline Analysis<\/strong><\/a><\/p>\n<p dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul readability=\"10\">\n<li dir=\"ltr\" readability=\"0\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of T-Cell Lymphoma<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"2\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>T-Cell Lymphoma Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"0\">\n<p dir=\"ltr\"><strong>T-Cell Lymphoma key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"6\">\n<p dir=\"ltr\"><strong>T-Cell Lymphoma Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"3\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>T-Cell Lymphoma market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\">The report is built using data and information traced from the researcher\u2019s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p dir=\"ltr\"><strong>Request for Sample PDF Report \u2013&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p dir=\"ltr\"><strong>T-Cell Lymphoma Therapeutics Landscape<\/strong><\/p>\n<p dir=\"ltr\"><em>The most common combination chemotherapy regimen that has been used is CHOP: cyclophosphamide, doxorubicin (or hydroxydaunorubicin), vincristine (also known as Oncovin), prednisolone (a steroid).&nbsp;Self (autologous) stem cell transplant is recommended for younger people with T-cell lymphoma who have responded well to initial chemotherapy. To further improve the treatment scenario, several pharma companies are actively working in the&nbsp;T-Cell Lymphoma Therapeutics Market.&nbsp;<\/em><\/p>\n<p dir=\"ltr\"><strong>Some of the key companies in the T-Cell Lymphoma Market includes:<\/strong><\/p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Applied Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Autolus<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Innate Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Affimed Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Solasia Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Soligenix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Myeloid Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CRISPR Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\">And many others<\/p>\n<p dir=\"ltr\"><strong>T-Cell Lymphoma Therapies covered in the report include:<\/strong><\/p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AT-104<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AUTO-5<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IPH4102<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AFM-13<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SP-02<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SGX-301<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MT-101<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CTX130<\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\">And many more<\/p>\n<p dir=\"ltr\"><strong>T-Cell Lymphoma Mechanism of Action (MoA)<\/strong><\/p>\n<ul readability=\"7\">\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">HSP90 heat-shock protein inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Apoptosis stimulants; Cell division inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Antibody-dependent cell cytotoxicity<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Cell replacements; Immunologic cytotoxicity<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Enhancer of zeste homolog 1 protein inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Enhancer of zeste homolog 2 protein inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">KIR3DL2 receptor antagonists<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene transference<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Immunologic cytotoxicity; Tlymphocyte replacements<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Phosphatidylinositol 3 kinase delta inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Phosphatidylinositol 3 kinase gamma inhibitors<\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies \u2013&nbsp; <a href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p dir=\"ltr\">1. Report Introduction<\/p>\n<p dir=\"ltr\">2. Executive Summary<\/p>\n<p dir=\"ltr\">3. T-Cell Lymphoma Current Treatment Patterns<\/p>\n<p dir=\"ltr\">4. T-Cell Lymphoma \u2013 DelveInsight\u2019s Analytical Perspective<\/p>\n<p dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p dir=\"ltr\">6. T-Cell Lymphoma Late Stage Products (Phase-III)<\/p>\n<p dir=\"ltr\">7. T-Cell Lymphoma Mid-Stage Products (Phase-II)<\/p>\n<p dir=\"ltr\">8. T-Cell Lymphoma Early Stage Products (Phase-I)<\/p>\n<p dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p dir=\"ltr\">10. Inactive Products<\/p>\n<p dir=\"ltr\">11. Dormant Products<\/p>\n<p dir=\"ltr\">12. T-Cell Lymphoma Discontinued Products<\/p>\n<p dir=\"ltr\">13. T-Cell Lymphoma Product Profiles<\/p>\n<p dir=\"ltr\">14. Key Companies in the T-Cell Lymphoma Market<\/p>\n<p dir=\"ltr\">15. Key Products in the T-Cell Lymphoma Therapeutics Segment<\/p>\n<p dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p dir=\"ltr\">17. T-Cell Lymphoma Unmet Needs<\/p>\n<p dir=\"ltr\">18. T-Cell Lymphoma Future Perspectives<\/p>\n<p dir=\"ltr\">19. T-Cell Lymphoma Analyst Review&nbsp;&nbsp;<\/p>\n<p dir=\"ltr\">20. Appendix<\/p>\n<p dir=\"ltr\">21. Report Methodology<\/p>\n<p dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p dir=\"ltr\"><strong>Download Sample PDF Report \u2013&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/t-cell-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p dir=\"ltr\">&nbsp;<\/p>\n<p dir=\"ltr\"><strong>Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n<p dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/spirometers-market\">Spirometers Market<br \/><\/a><\/strong>\u201cSpirometers&nbsp;Market\u201d research report provides comprehensive insights into the historical and forecasted&nbsp;Spirometers&nbsp;market size, share, and trends as well as the key companies and emerging products in the market.&nbsp;&nbsp;<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=tcell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432 <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tcell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed\" alt width=\"1px\" height=\"1px\"><\/p>\n<p><noscript><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tcell-lymphoma-therapeutics-analysis-fda-and-eu-approvals-recents-breakthroughs-clinical-trials-emerging-therapies-and-key-companies-autolus-solasia-soligenix-crispr-therapeutics-affimed\" alt width=\"1px\" height=\"1px\"><\/noscript><br \/>\n <br \/>Published Wed, 13 Jul 2022 18:45:21 -0500<\/p>\n","protected":false},"excerpt":{"rendered":"<p>T-Cell Lymphoma Therapeutics Analysis | FDA and EU Approvals, Recents Breakthroughs, Clinical Trials, Emerging Therapies, and Key Companies | Autolus, Solasia, Soligenix, CRISPR Therapeutics, Affimed \u201cDelveinsight Business Research LLP\u201d As per DelveInsight, the T-Cell Lymphoma Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":8297,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/8299"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=8299"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/8299\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/8297"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=8299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=8299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=8299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}